EUVIMEDEUVIMED entdecken
Crossref

Systemic therapies at the end of life vary by patient and practice

Mary Beth Nierengarten

Cancer · 2023

DOI: 10.1002/cncr.35053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Mary Beth Nierengarten. Hauptthemen laut MEDLINE: Terminal Care, Insurance, Neoplasms. Die Arbeit nennt 1 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, whether or not patients with cancer at the end of life received systemic therapies depended partly on race, insurance type, and the practice where they were treated, but experts debate whether decisions based on these factors are in patients’ best interests. In addition, staging laparoscopy for patients with pancreatic cancer to help to determine the best treatment option is a valuable practice, and pirtobrutinib is effective in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma for whom prior treatments with BTK inhibition and venetoclax failed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Terminal CareInsuranceNeoplasmsHumansDecision MakingDeathImmunotherapy

Zitieren

APA

Nierengarten, M. B. (2023). Systemic therapies at the end of life vary by patient and practice. Cancer. https://doi.org/10.1002/cncr.35053

Vancouver

Nierengarten MB. Systemic therapies at the end of life vary by patient and practice. Cancer. 2023. doi:10.1002/cncr.35053

BibTeX
@article{Nierengarten2023,
  author = {Nierengarten, Mary Beth},
  title = {Systemic therapies at the end of life vary by patient and practice},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.35053}
}
Kostenlos starten →